Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Alterity Therapeutics is a late clinical-stage biotech company focused on developing treatments for serious neurodegenerative ...

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

Atrophy Advisor aids in managing GA in AMD by integrating progression and lifespan estimates to guide treatment decisions. GA progression is influenced by phenotypic, demographic, and genetic factors, ...

Atrophy Advisor aids physicians in personalizing treatment for geographic atrophy in age-related macular degeneration, enhancing patient care and outcomes. Avery Kerwin, MD, the first author of the ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Disease-modifying therapies (DMTs) significantly slow brain volume loss in multiple sclerosis patients. Reduced brain volume loss directly correlates with decreased long-term disability progression in ...